XML 45 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Capital Stock and Share-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
The fair values of stock options granted in each period presented were estimated using the following weighted-average assumptions:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Risk-free rate0.46 %— 0.69 %2.59 %
Expected volatility62.78 %— 62.84 %64.63 %
Expected term (in years)7— 77
Summary of Stock Option Activity
A summary of the stock option activity for the nine months ended September 30, 2020 is presented below:
 Options OutstandingOptions Exercisable
Number of
Shares		Price per Share
Range		Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value (1)		Number of
Shares		Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value (1)
(in thousands, except share, per share and weighted-average data)
Balance, January 1, 20203,160,397 
$1.18 - $7.37
$2.72 $14,460 1,835,799 $2.28 $9,198 
Granted70,000 
$6.27 - $7.59
$6.65 
Exercised(688,495)
$1.18 - $4.43
$2.84 
Canceled(100,187)
$1.27 - $4.75
$3.33 
Balance, September 30, 20202,441,715 
$1.18 - $7.59
$2.77 $7,971 1,396,231 $2.18 $5,323 
 
(1)The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only. The aggregate intrinsic value is based on the closing price of our common stock on the Nasdaq Capital Market, as applicable, on the respective dates.
Summary of Restricted Stock Awards and Units
The following table summarizes the number of unvested shares underlying our restricted stock awards and RSUs and the value of our unvested restricted stock awards and RSUs:
(in thousands, except share and weighted-average share data)
Number of Unvested SharesWeighted Average Grant Date Fair ValueAggregate Grant Date Fair Value of Unvested Shares
Balance, January 1, 2020502,102 $3.32 $1,667 
Granted149,302 6.48 967 
Vested(205,267)2.86 (587)
Balance, September 30, 2020446,137 $4.58 $2,047 
The following is a summary of our stock unit activity under the Deferred Compensation Plan for the nine months ended September 30, 2020:
(in thousands, except stock units and weighted-average share data)
Number of Stock UnitsWeighted Average Grant Date Fair Value per ShareIntrinsic Value Outstanding
Balance, January 1, 2020629,003 $2.09 $4,585 
  Granted47,015 6.70 281 
  Issued(47,377)1.65 — 
Balance, September 30, 2020628,641 $2.37 $3,759 
Details of Equity Transactions
The following table details our equity transactions during the nine months ended September 30, 2020:
 Preferred StockCommon StockTreasury StockAdditional
Paid-in
Capital		Accumulated DeficitTotal
 Shares$Shares$Shares$$$$
(in thousands, except share data)
Balance, January 1, 2020, as previously reported— $— 30,149,105 $32 1,639,791 $(4,337)$88,022 $(16,248)$67,469 
Exercise of stock options— — 316,504 — — — 1,198 — 1,198 
Share-based compensation— — 55,668 — — — 502 — 502 
Net income— — — — — — — (1,116)(1,116)
Forfeitures of restricted stock— — (34,700)— — — (276)— (276)
Balance, March 31, 2020— $— 30,486,577 $32 1,639,791 $(4,337)$89,446 $(17,364)$67,777 
Exercise of stock options— — 346,461 — — — 726 — 726 
Share-based compensation— — 11,600 — — — 465 — 465 
Deferred compensation issuance— — 47,377 — — — 78 — 78 
Net income— — — — — — — 1,369 1,369 
Forfeitures of restricted stock— — (61,530)— — — (410)— (410)
Purchase of treasury stock— — (32,950)— 32,950 (204)— — (204)
Balance, June 30, 2020— $— 30,797,535 $32 1,672,741 $(4,541)$90,305 $(15,995)$69,801 
Exercise of stock options— — 25,530 1 — — 33 — 34 
Share-based compensation— — — — — — 571 — 571 
Net income— — — — — — — 3,102 3,102 
Forfeitures of restricted stock— — 14,700 — — — 125 — 125 
Purchase of treasury stock— — (14,700)— 14,700 (125)— — (125)
Balance, September 30, 2020— $— 30,823,065 $33 1,687,441 $(4,666)$91,034 $(12,893)$73,508 
The following table details our equity transactions during the nine months ended September 30, 2019:
 Preferred StockCommon StockTreasury StockAdditional
Paid-in
Capital		Accumulated DeficitTotal
 Shares$Shares$Shares$$$$
(in thousands, except share data)
Balance, January 1, 2019, as previously reported1,321,514 $1 27,956,401 $30 1,253,105 $(2,117)$85,745 $(21,305)$62,354 
Exercise of stock options— — 189,312 — — — 185 — 185 
Share-based compensation— — — — — — 343 — 343 
Stock dividends to Carilion Clinic— — — — — — 83 (83)— 
Net income— — — — — — — 1,126 1,126 
Balance, March 31, 20191,321,514 $1 28,145,713 $30 1,253,105 $(2,117)$86,356 $(20,262)$64,008 
Exercise of stock options— — 207,786 — — — 182 — 182 
Share-based compensation— — — — — — 378 — 378 
Stock dividends to Carilion Clinic— — — — — — 90 (90)— 
Net income— — — — — — — 841 841 
Purchase of treasury stock— — (52,733)— 52,733 (220)— — (220)
Balance, June 30, 20191,321,514 $1 28,300,766 $30 1,305,838 $(2,337)$87,006 $(19,511)$65,189 
Exercise of stock options— — 83,204 1 — — 70 — 71 
Share-based compensation— — 16,286 — — — 420 — 420 
Stock dividends to Carilion Clinic— — 770,454 — — — 113 (113)— 
Preferred stock to common stock conversion(1,321,514)(1)1,321,514 1 — — — — — 
Net income— — — — — — — 1,230 1,230 
Purchase of treasury stock— — (333,953)— 333,953 (2,000)— — (2,000)
Balance, September 30, 2019— $— 30,158,271 $32 1,639,791 $(4,337)$87,609 $(18,394)$64,910